WO2013109096A1 - 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 - Google Patents
3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 Download PDFInfo
- Publication number
- WO2013109096A1 WO2013109096A1 PCT/KR2013/000423 KR2013000423W WO2013109096A1 WO 2013109096 A1 WO2013109096 A1 WO 2013109096A1 KR 2013000423 W KR2013000423 W KR 2013000423W WO 2013109096 A1 WO2013109096 A1 WO 2013109096A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- galactose
- acid
- anhydro
- agarose
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
Definitions
- the present invention relates to 3,6-anhydro-L-galactose prepared according to chemical and enzymatic methods and to industrial use using the physiological efficacy thereof.
- Agar or agarose
- Agar the major polysaccharide of red algae, has two monosaccharides, 3,6-anhydro-L-galactose and D-galactose, in which alpha 1,3 and beta 1,4 bonds are cross-linked.
- Polymer Agaro-oligosaccharides produced by non-specific hydrolysis using agarose with chemical catalysts such as hydrochloric acid, sulfuric acid, and acetic acid are widely known to have excellent physiological activities such as antioxidant, anti-inflammatory, anti-cancer, whitening, and anti-allergic functions. Due to these various physiological activities, agaro oligosaccharides and disaccharides, neoagarobiose, are widely used as functional substances in the food industry and the beauty industry.
- hydrolysis through chemical treatment has the advantage that it can be applied to commercialization because of low production cost and simple processing conditions, but the yield is very low when decomposing the specific bond to obtain the desired product because the non-specifically cleaved bond is obtained.
- There are disadvantages Choen et al (2005) Food Technol Biotechnol. 43 (1) 29-36).
- enzymes that produce monosaccharides by specifically cleaving 3,6-anhydro-L-galactose bonds have recently been reported, but studies to isolate, purify and quantify 3,6-anhydro-L-galactose only from reaction products have been reported. It is inadequate.
- Another object of the present invention is to identify the physiological activity of the 3,6- anhydro-L-galactose and to use it industrially.
- the present invention by reacting agarose with a weak acid of 0.5 to 60% (w / v) concentration for 30 minutes to 6 hours at a temperature of 100 to 200 rpm in the temperature range of 40 to 150 °C Preparing agar oligosaccharides; And reacting the agar oligosaccharide with agarose degrading enzyme and neoagarobiose hydrolase for 30 minutes to 7 days at 0 to 200 rpm in a temperature range of 20 to 40 ° C. 3,6- Provided is a method for preparing anhydro-L-galactose.
- the agarose degrading enzyme may be an enzyme that cleaves ⁇ -1,4-glycosidic bonds between D-galactose and 3,6-anhydro-L-galactose of agarose. Specifically, it may be represented by the amino acid sequence described in SEQ ID NO: 1.
- the neoagarobiose hydrolase may be represented by the amino acid sequence described in SEQ ID NO: 3.
- the agarose degrading enzyme and neoagarobiose hydrolase may be derived from Saccharophagus degradans 2-40.
- adsorption chromatography and gel permeation chromatography are sequentially performed on 3,6-anhydro-L-galactose to give 3,6-anhydro-L-galactose.
- the method may further include separating and purifying L-galactose.
- the present invention also provides a cosmetic composition for skin whitening or moisturizing comprising 3,6-anhydro-L-galactose.
- the present invention also provides cosmetic uses for skin whitening or moisturizing 3,6-anhydro-L-galactose.
- the present invention also provides a pharmaceutical composition for the prevention or treatment of skin pigmentation diseases, including 3,6-anhydro-L-galactose.
- the present invention also provides the use of 3,6-anhydro-L-galactose for the preparation of a pharmaceutical composition for the prevention or treatment of skin pigmentation diseases.
- the present invention also provides a mammal, preferably a human, in need of a whitening or moisturizing comprising administering an effective amount of 3,6-anhydro-L-galactose in the form of a pharmaceutical or cosmetic composition containing the same.
- a cosmetic or medical method for whitening or moisturizing the skin is provided.
- the present invention also relates to conditions, diseases and / or lesions, preferably skin conditions associated with the control of pigmentation, comprising applying to the skin a pharmaceutical or cosmetic composition containing 3,6-anhydro-L-galactose Occurs locally on the skin with an increased synthesis of melanin pigments, and to treat one or more selected from blemishes, freckles, black spots, birthmarks, pigmentation by drugs, pigmentation after inflammation, and hyperpigmentation occurring in dermatitis Provide cosmetic or medical methods.
- the invention also provides a pharmaceutical composition for the prophylaxis or treatment of inflammatory diseases comprising 3,6-anhydro-L-galactose.
- the present invention also provides a method of treating inflammatory disease in an animal comprising administering to the individual a composition for the prevention or treatment of an inflammatory disease comprising a pharmaceutically effective amount of 3,6-anhydro-L-galactose.
- the present invention also provides the use of 3,6-anhydro-L-galactose for the preparation of a pharmaceutical composition for the prevention or treatment of an inflammatory disease.
- the present invention has the effect of producing a high yield of monosaccharide 3,6-anhydro-L-galactose through the enzymatic treatment after the oligosaccharide is prepared under mild chemical treatment conditions to minimize the overdegradation effect of the chemical treatment .
- the present invention also identifies the first physiological activity of 3,6-anhydro-L-galactose, such as whitening, moisturizing, antioxidant, anti-inflammatory, so that it can be used in the food, cosmetics, and pharmaceutical fields. Therefore, 3,6-anhydro-L-galactose, which is considered as a by-product or fermentation inhibitor in the production of red algae-derived bioenergy, can be applied to generate high value-added substances in the bioenergy industry.
- FIG. 1 illustrates a process for preparing 3,6-anhydro-L-galactose in agarose according to the present invention, in which DP denotes a degree of polymerization of polysaccharides.
- Figure 2 is a TLC result showing the process for preparing and purifying 3,6-anhydro-L-galactose in agarose, in the processing step (lane 1 is agarose, lane 2 is acetic acid hydrolyzate) , Lane 3 is Aga50D reaction product, lane 4 is sdNABH reaction product, lane 5 is 3,6-anhydro-L-galactose separated by silica gel chromatography, lane 6 is 3,6 purified by biogel P2 chromatography. -Anhydro-L-galactose, AHG on the Y axis is 3,6-anhydrogalactose, and NAB refers to neoagarobiose.
- Figure 3 shows the silica gel chromatography TLC results of the first step of 3,6-anhydro-L-galactose purification, AHG in the figure refers to 3,6-anhydrogalactose.
- FIG. 4 shows GC / MS total ion chromatograms of D-form 3,6-anhydrogalactose standard (a) and 3,6-anhydro-L-galactose (b) purified through the present invention. will be.
- Figure 6 shows the results of 2D-HSQC NMR analysis of the purified purified 3,6- anhydro-L-galactose.
- FIG. 7 shows the whitening effect of 3,6-anhydro-L-galactose, neoagarobiose, D-galactose and 3,6-anhydro-D-galactose, in which ⁇ -MSG is ⁇ -melanocyte.
- -stimulating hormones, NAB, neoagarobiose, D-AHG and L-AHG refer to 3,6-anhydrogalactose of D-form and L-form, respectively.
- Figure 9 shows the effect of L-AHG on tyrosinase expression induced by ⁇ -MSH in HEMs
- A is the result of tyrosinase expression of cells exposed to ⁇ -MSH after treatment by concentration of L-AHG
- B is a graph showing the result of A as the relative intensity of tyrosinase to ⁇ -actin.
- Figure 10 shows the effect of L-AHG on TRP-1 expression induced by ⁇ -MSH in HEMs
- A is the result of TRP-1 expression of cells exposed to ⁇ -MSH after the concentration-dependent treatment of L-AHG
- B is a graph showing the result of A as the relative intensity of TRP-1 to ⁇ -actin.
- Figure 11 shows the effect of L-AHG on tyrosinase activity in vitro.
- Figure 12 shows the effect of L-AHG on HAS2 expression in human keratinocytes
- A is the HAS2 expression level after the hourly treatment of L-AHG of 100 ⁇ g / mL
- B is HAS2 after treatment by concentration of L-AHG Expression level.
- Figure 13 shows the effect of L-AHG on the phosphorylation of ERK in human keratinocytes
- A is the result of ERK phosphorylation after hourly treatment of L-AHG of 100 ⁇ g / mL
- B after treatment by concentration of L-AHG ERK phosphorylation results.
- Figure 14 shows the effect of L-AHG on the phosphorylation of AKT in human keratinocytes
- A is the result of AKT phosphorylation after hourly treatment of L-AHG of 100 ⁇ g / mL
- B after treatment by concentration of L-AHG AKT phosphorylation results.
- agarose oligosaccharide is prepared by reacting agarose with a weak acid having a concentration of 0.5 to 60% (w / v) for 30 minutes to 6 hours at a temperature of 40 to 150 ° C. under a condition of 100 to 200 rpm. ; And reacting the agar oligosaccharide with agarose degrading enzyme and neoagarobiose hydrolase for 30 minutes to 7 days at 0 to 200 rpm in a temperature range of 20 to 40 ° C. 3,6- It relates to a method for preparing anhydro-L-galactose.
- the method for preparing 3,6-anhydro-L-galactose of the present invention is an exo-type of hydrolyzing agarose under mild conditions using a weak acid, and producing a disaccharide of the agar oligosaccharide obtained from the acid hydrolysis product. Reacts with agarose degrading enzymes to produce neoagarobiose, and further reacts with neoagarobiose hydrolase to produce monosaccharide galactose and 3,6-anhydro-L-galactose. .
- the 3,6-anhydro-L-galactose may have a structure of Formula 1:
- the first step is to prepare agarose oligosaccharides by treating agarose with a weak acid.
- the weak acid may include acetic acid, formic acid, succinic acid, citric acid, citric acid, malic acid, maleic acid, or oxalic acid. More than one species can be used.
- the weak acid may be used at a concentration of 0.5 to 60% (w / v) in consideration of production cost and separation of salts generated after neutralization of the weak acid. More specifically, it may be used at a concentration of 20 to 40% (w / v).
- the reaction of the agarose and the weak acid may be carried out for 30 minutes to 6 hours under conditions of 100 to 200 rpm in the temperature range of 40 to 150 °C. If it is in the above range can be minimized the degradation products of the agarose by weak acid.
- the reaction product obtained after the reaction can be obtained by washing and drying in order to remove the weak acid and peroxide products remaining in the agar oligosaccharide.
- the lower alcohol having 1 to 6 carbon atoms may be used as the washing solvent, but is not particularly limited thereto.
- the second step is to prepare 3,6-anhydro-L-galactose by enzymatic digestion of agaro oligosaccharides.
- the enzymatic digestion is a disaccharide, neoagar, by treating an exo type agarose degrading enzyme.
- the bios are produced, and then treated with neoagarobiose hydrolase to decompose D-galactose and 3,6-anhydro-L-galactose.
- the enzyme reaction may be carried out for 30 minutes to 7 days at 0 to 200 rpm conditions in a temperature range of 20 to 40 °C.
- the enzyme reaction is described in more detail as follows.
- the agarose degrading enzyme that decomposes agao oligosaccharides to produce a disaccharide, neoagarobiose, is ⁇ -1,4-glyco between D-galactose of agarose and 3,6-anhydro-L-galactose.
- An enzyme that cleaves side bonds hereinafter referred to as 'Aga50D' can be used.
- the agarose degrading enzyme has an amino acid sequence of SEQ ID NO: 1 and sequence identity with the sequence of 80% or more, 85% or more, 90% or more, 93% or more, 94% or more, 95% or more, 96% or more , At least 97%, at least 98%, and at least 99%.
- the polypeptide has a certain ratio (eg, 80%, 85%, 90%, 95%, or 99%) of sequence identity with respect to another sequence, when aligning the two sequences, By comparison it is meant that the amino acid residues in this ratio are identical.
- the alignment and percent homology or identity may be determined by any suitable software program known in the art, such as those described in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FM Ausubel et al. (Eds) 1987 Supplement 30 section 7.7.18). Can be determined using Preferred programs include the GCG Pileup program, FASTA (Pearson et al. 1988 Proc. Natl Acad.
- BLAST BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med
- NCIB NLM NIH Bethesda
- ALIGN Plus Alternativeific and Educational Software, PA
- Another sequence software program that can be used is the TFASTA Data Searching Program available from Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison, Wis.).
- protein and “polypeptide” are used interchangeably herein. Conventional one or three letter codes are used herein for amino acid residues.
- the enzyme may be derived from Saccharophagus degradans 2-40, but is not particularly limited thereto.
- the enzyme can be transcribed and translated through DNA segments, ie coding genes, involved in producing polypeptides comprising the intervening sequences between individual coding segments as well as regions before and after the coding region of the enzyme.
- DNA segments ie coding genes, involved in producing polypeptides comprising the intervening sequences between individual coding segments as well as regions before and after the coding region of the enzyme.
- it may be a sequence set forth in SEQ ID NO: 2, but is not particularly limited thereto.
- trehalose degrading enzyme is saccharide as a wave Gus de gras thiooxidans separated from the water, the supernatant or the supernatant culture of the (Saccharophagus degradans) and can be purified, and genetically engineered using recombinant techniques saccharide par Gus de gras thiooxidans (Saccharophagus degradans ) can be produced and separated by strains or artificial chemical synthesis.
- the agarose degrading enzyme of the present invention may be used as a supernatant or supernatant of Saccharophagus degradans culture or by transforming an edible strain, such as yeast, to culture supernatant or supernatant. Can be used as a substitute.
- the term “recombinant” means that the cell, nucleic acid, protein or vector has been modified by introduction of a heterologous nucleic acid or protein or alteration of the original nucleic acid or protein, or The cell refers to a cell derived from such a modified cell. That is, for example, a recombinant cell expresses a gene that is not found within the original (non-recombinant) form of the cell, or alternatively expresses an original gene that is abnormally expressed or not expressed at all upon expression. Expression.
- nucleic acid encompasses single- or double-stranded DNA, RNA, and chemical variants thereof.
- Nucleic acid and polynucleotide can be used interchangeably herein. Because the genetic code is degenerate, one or more codons can be used to encode a particular amino acid, and the invention encompasses polynucleotides encoding a particular amino acid sequence.
- introduction of inserting a nucleic acid sequence into a cell means “transfection”, or “transformation” or “transduction” and refers to the integration of the nucleic acid sequence into eukaryotic or prokaryotic cells. Mention is included, wherein the nucleic acid sequence is integrated into the cell's genome (eg, chromosome, plasmid, pigment, or mitochondrial DNA), converted to autonomic replicon, or transiently expressed.
- the cell's genome eg, chromosome, plasmid, pigment, or mitochondrial DNA
- the reaction of the agar oligosaccharide and agarose degrading enzyme may be carried out for 30 minutes to 7 days at 0 to 200 rpm conditions in a temperature range of 20 to 40 °C. More specifically, it may be carried out for 1 day to 4 days at 100 to 150 rpm conditions in a temperature range of 25 to 35 °C.
- the agar oligosaccharide When the agar oligosaccharide is in a powder state, it may be used in a conventional buffer solution, but is not particularly limited thereto.
- neoagarobiose hydrolase capable of decomposing neoagarobiose produced through the enzymatic reaction into D-galactose and 3,6-anhydro-L-galactose is the amino acid sequence of SEQ ID NO.
- a protein having the neoagarobiose hydrolytic activity is also included in the scope of the enzyme of the present invention.
- Amino acid sequences having at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and at least 99% sequence identity with the sequence ( Hereinafter referred to as 'sdNABH').
- the enzyme may be derived from Saccharophagus degradans 2-40, but is not particularly limited thereto.
- the enzyme can be transcribed and translated through DNA segments, ie coding genes, involved in producing polypeptides comprising the intervening sequences between individual coding segments as well as regions before and after the coding region of the enzyme.
- DNA segments ie coding genes, involved in producing polypeptides comprising the intervening sequences between individual coding segments as well as regions before and after the coding region of the enzyme.
- sequence as set forth in SEQ ID NO: 4, but is not particularly limited thereto.
- the neo-agar in BIOS hydrolase is Saccharomyces par Gus de Jerusalem thiooxidans separated from the water, the supernatant or the supernatant culture of the (Saccharophagus degradans) and can be purified, and genetically engineered using recombinant techniques saccharide par Gus de gras thiooxidans (Saccharophagus degradans ) can be produced and separated by strains or artificial chemical synthesis.
- the neoagarobiose hydrolase of the present invention is supernatant or supernatant of Saccharophagus degradans culture, or culture supernatant of yeast transformed by transforming edible strains such as yeast. Alternatively, supernatant can be used.
- neoagarobiose and neoagarobiose hydrolase may be carried out for 30 minutes to 7 days at a temperature of 0 to 200 rpm in the temperature range of 20 to 40 °C. More specifically, it may be carried out for 1 day to 4 days at 100 to 150 rpm conditions in a temperature range of 25 to 35 °C.
- the method for preparing 3,6-anhydro-L-galactose of the present invention may be further carried out by separating and purifying only 3,6-anhydro-L-galactose in the decomposition product of neoagarobiose.
- the 3,6-anhydro-L-galactose may be separated and purified to a high purity of approximately 96% by sequentially performing silica gel chromatography, which is an adsorption chromatography, and bio gel P2 chromatography, which is a gel permeation chromatography.
- the purified product was analyzed by 1 H-NMR and 2D-Heteronuclear Single Quantum Coherence (HSQC) NMR analysis to compare the structure of 1 H ppm and 13 C ppm of 3,6-anhydro-L-galactose. I can sympathize.
- HSQC 2D-Heteronuclear Single Quantum Coherence
- the method of the present invention produces 76 g of agaoligosaccharides through chemical hydrolysis from 100 g of agarose, and 37.55 g of neoagarobiose and 15.21 using Aga50D and sd NABH enzymes. g of 3,6-anhydro-L-galactose is produced respectively, and 3.98 g of pure 3,6-anhydro-L-galactose can be purified through two chromatographic purification processes.
- the present invention also relates to a skin whitening or moisturizing cosmetic composition comprising 3,6-anhydro-L-galactose.
- the present invention also provides cosmetic uses for skin whitening or moisturizing 3,6-anhydro-L-galactose.
- the 3,6-anhydro-L-galactose has a higher whitening activity than arbutin, which is most widely known as a conventional whitening substance, and in a concentration-dependent manner expresses the expression of tyrosinase, TRP-1, etc., which are involved in promoting melanin synthesis. There is a characteristic to suppress.
- 3,6-anhydro-L-galactose exhibits a whitening effect by inhibiting the expression of enzymes rather than inhibiting tyrosinase activity.
- 3,6-anhydro-L-galactose is characterized by promoting the expression of HAS2 protein, a moisturizing marker involved in the synthesis of hyaluronic acid.
- HAS2 expression is regulated by various inflammatory signaling pathways, such as ERK and AKT, wherein 3,6-anhydro-L-galactose increases the phosphorylation of ERK and AKT and increases phosphorylation.
- ERK and AKT can increase HAS2 expression.
- the 3,6-anhydro-L-galactose may be synthesized or used without limitation, prepared according to the method for preparing 3,6-anhydro-L-galactose according to the present invention.
- a cosmetic or cosmetic comprising a composition containing the 3,6- anhydro-L-galactose itself or a cosmetically acceptable carrier as a functional ingredient, in the form of a general emulsion formulation and solubilized formulation It can be prepared as.
- Cosmetics of the emulsified formulations include nutrient cosmetics, creams, essences, etc., and cosmetics of the solubilized formulations are flexible cosmetics.
- Suitable cosmetic formulations include, for example, emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes), nonionic vesicles obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, for example. It may be provided in the form of a dispersant, cream, skin, lotion, powder, ointment, spray or cone stick.
- It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
- the cosmetics in addition to the 3,6- anhydro-L-galactose of the present invention, fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents (foaming agents) ), Fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipids It may contain adjuvants commonly used in the field of cosmetics such as vesicles or any other ingredients conventionally used in cosmetics.
- the 3,6-anhydro-L-galactose When used as a food or food additive, the 3,6-anhydro-L-galactose may be added as it is or may be used with other food or food ingredients, and a conventional method It can be suitably used according to.
- the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
- the composition of the present invention in food production is added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw material.
- the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .
- the invention also relates to a pharmaceutical composition for the prevention or treatment of skin pigmentation disorders comprising 3,6-anhydro-L-galactose.
- the present invention also provides the use of 3,6-anhydro-L-galactose for the preparation of a pharmaceutical composition for the prevention or treatment of skin pigmentation diseases.
- compositions of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
- compositions of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and other external preparations and sterile injectable solutions, respectively, in accordance with conventional methods, preferably creams. , Gels, patches, sprays, ointments, warnings, lotions, linings, pasta or cataplasma.
- Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants that are commonly used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose, or the like.
- excipients such as starch, calcium carbonate, sucrose, or the like.
- lactose, gelatin and the like are preferably mixed.
- lubricants such as magnesium styrate talc may also be used.
- Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
- Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
- base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the pharmaceutical composition of the present invention is a skin external preparation formulation that can be applied to the skin, and is used in the form of a skin external preparation of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma. It may be prepared by using the composition, but is not limited thereto.
- compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
- the composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day.
- Topical administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the present invention also provides a mammal, preferably a human, in need of a whitening or moisturizing comprising administering an effective amount of 3,6-anhydro-L-galactose in the form of a pharmaceutical or cosmetic composition containing the same. It relates to a cosmetic or medical method for whitening or moisturizing the skin.
- the present invention relates to skin conditions, diseases and / or lesions, preferably associated with the regulation of pigmentation, comprising applying to the skin a pharmaceutical or cosmetic composition containing 3,6-anhydro-L-galactose.
- a pharmaceutical or cosmetic composition containing 3,6-anhydro-L-galactose preferably containing 3,6-anhydro-L-galactose.
- the increase in the synthesis of melanin pigment occurs locally on the skin and treats one or more selected from blemishes, freckles, black spots, birthmarks, pigmentation by drugs, pigmentation after inflammation, and hyperpigmentation occurring in dermatitis.
- blemishes blemishes, freckles, black spots, birthmarks, pigmentation by drugs, pigmentation after inflammation, and hyperpigmentation occurring in dermatitis.
- the frequency of application of the pharmaceutical or cosmetic composition containing 3,6-anhydro-L-galactose can vary significantly depending on the needs of each subject, the frequency of application being monthly to 10 times a day, preferably weekly to 1 Four times a day, more preferably three to three times a week, even more preferably once or twice a day are proposed.
- the present invention provides for the treatment, care and / or treatment of the skin, preferably of the skin of the face, neck, neckline, hands, armpits, groin, elbows and / or knees, more preferably of the facial, neck and / or hands. It relates to the use of 3,6-anhydro-L-galactose in the manufacture of a pharmaceutical or cosmetic composition for cleaning.
- the invention also provides a pharmaceutical composition for the prophylaxis or treatment of inflammatory diseases comprising 3,6-anhydro-L-galactose.
- the present invention also provides a method of treating inflammatory disease in an animal comprising administering to the individual a composition for the prevention or treatment of an inflammatory disease comprising a pharmaceutically effective amount of 3,6-anhydro-L-galactose.
- the present invention provides the use of 3,6-anhydro-L-galactose for the preparation of a pharmaceutical composition for the prevention or treatment of an inflammatory disease.
- the 3,6-anhydro-L-galactose has an antioxidant activity that inhibits the production of nitrite (nitrite, NO 2 ), which is neo-agarobiose, galactose, and D-form, other disaccharides and monosaccharides constituting seaweeds.
- nitrite nitrite, NO 2
- NO 2 nitrite
- 3,6- anhydrogalactose of the highest it can be used as a pharmaceutical composition for the prevention or treatment of inflammatory diseases (see Figure 8).
- the individual capable of administering the pharmaceutical composition for preventing or treating the inflammatory disease includes all animals.
- it may be an animal other than a human such as a dog, a cat, and a mouse.
- An effective amount of the active ingredient of the pharmaceutical composition means an amount required to achieve treatment of the disease.
- Treatment also includes, but is not limited to, alleviating the symptom, removing the cause of the symptom temporarily or permanently, or preventing or slowing the appearance of the symptom and the progression of the disease, disorder or condition described above.
- Agarose a representative polysaccharide constituting seaweed
- acetic acid 5% (w / v) of agarose was reacted with 3M acetic acid at 80 ° C. for 70 minutes and then dried to remove acetic acid.
- 3M acetic acid 3M acetic acid
- ethanol ethanol to remove the residual acetic acid and hydrolyzate that can be produced during the hydrolysis to produce agarose oligosaccharide in the pure powder state (Fig. 2).
- Aga50D an exo-type disaccharide-producing enzyme, in order to decompose into monosaccharides D-galactose and 3,6-anhydro-L-galactose from the acid hydrolyzate produced in Example 1 -0040438) to produce neoagarobiose as a reaction product.
- the reaction product of Aga50D with sd NABH enzyme (see Korean Patent Publication No. 2010-0108241) to produce monosaccharides D-galactose and 3,6-anhydro-L-galactose from neoagarobiose after completion of the Aga50D reaction I was.
- Enzyme reaction was performed by dissolving 5% (w / v) agatooligosaccharide in 100 mL of 50 mM Tris-HCl buffer (pH 7.4) and reacting at 30 ° C. at 150 rpm for 3 days.
- the amount of enzyme used in the enzyme reaction was Amg50D 10mg, sd NABH 2.5mg (Fig. 2).
- Biogel P2 chromatography can purify only 3,6-anhydro-L-galactose from disaccharides and low agarose oligosaccharides.
- the mobile phase used was water and the volume per fraction was 2 mL. Only fractions showing only 3,6-anhydro-L-galactose spot on TLC of each fraction were collected to obtain high purity 3,6-anhydro-L-galactose (FIG. 2).
- agaoligosaccharide was produced by chemical hydrolysis from 100 g of agarose through Examples 1 to 3, and 37.55 g of neoagarobiose and 15.21 using Aga50D and sd NABH enzymes. g of 3,6-anhydro-L-galactose were produced, respectively. Also, 3.98 g of pure 3,6-anhydro-L-galactose was purified through two chromatographic purification procedures.
- High purity 3,6-anhydro-L-galactose produced in Example 3 was quantified by analysis by GC / MS.
- the derivatization process for GC / MS analysis is as follows. The purified sample was dried with a speed bag, and 50 ⁇ l of 2% (w / v) O-methylhydroxylamine hydrochloride in pyridine was added thereto and reacted at 75 ° C. for 30 minutes. In addition, 80 ⁇ l of N-methyl-N- (trimethylsilyl) trifluoroacetamide (N-methyl-N- (trimethylsilyl) trifluoroacetamide) was added thereto and reacted at 40 ° C. at 150 rpm for 30 minutes.
- the instrument conditions for GC / MS analysis are as follows.
- the column used for analysis was a DB5-MS capillary column, and the GC column temperature conditions were first maintained at 100 ° C. for 3.5 minutes, and then heated up to 160 ° C. for 20 minutes. Thereafter, the temperature was raised to 200 ° C. and maintained for 15 minutes. Finally, the temperature was maintained at 280 ° C. for 5 minutes. 1 ⁇ l of sample was analyzed at a split ratio of 9.6 (FIG. 4).
- Neo-agarobiose and D-galactose the sugars that make up albutin and red algae, are the most widely used whitening agents before the treatment of the ⁇ -melanosite-stimulatine hormone, a hormone that promotes melanin production.
- 3,6-anhydro-D-galactose, and 3,6-anhydro-L-galactose at 1, 10, and 100 ⁇ g / mL, respectively, followed by reaction with ⁇ -melatosite-stimulin hormone. was carried out. After incubating for 4 days, the melanin content was analyzed by measuring the absorbance at 475 nm.
- the concentration of nitrite (NO 2 ) in RAW264.7 cell culture was measured by the Griess reaction method.
- the cells were treated with lipopolysaccahrides at a concentration of 2 ⁇ g / mL, while neoagarobiose, galactose, 3,6-anhydro-D-galactose, and 3,6-anhydro-L-galactose were 50 , 100, 200 ⁇ g / mL concentration and then treated together to measure the antioxidant activity. After culturing together for 24 hours, 540 nm absorbance was measured and analyzed for antioxidant activity.
- Melanin is a natural pigment that determines the color of skin and hair.
- the main known function of melanin is to protect against DNA damage by ultraviolet radiation by absorbed and scattered ultraviolet radiation.
- excessive melanogenesis or abnormal distribution can cause irregular skin hyperpigmentation, such as blemishes, freckles, senile sunspots, and the like.
- Ultraviolet irradiation increases tyrosinase and tyrosinase related proteins (TRPs) by increasing the levels of ⁇ -melanocyte-stimulating hormone (ACH), ACTH and their related receptor, melanocortin 1 receptor (MC1R).
- ACH ⁇ -melanocyte-stimulating hormone
- M1R melanocortin 1 receptor
- melanin biosynthesis enzymes is a copper-containing glycoprotein, tyrosinase, which is an important rate-regulating step enzyme for melanin synthesis in melanocytes produced only in certain organelles, i.e. Therefore, reduction of tyrosinase expression is considered a good strategy for inhibiting skin pigmentation.
- TRP-1 is structurally associated with tyrosinase, shares ⁇ 40% amino acid homology, and is present in the melanin bodies like tyrosinase. Previous studies have reported that mutations in TRP-1 result in pale skin or hair color, and in certain types of ocular scleroderma. It is also suggested that TRP-1 plays a role in melanin biosynthesis because inhibition of TRP-1 expression is associated with hypopigmentation.
- Human epidermal melanocytes derived from neonatal foreskin Human epidermal melanocytes, HEMs, Cascade Biologics (Oregon, USA) were used as cells for this purpose.
- the cells were cultured at 37 ° C. in a humidified atmosphere containing 5% CO 2 .
- the growth medium for HEMs is Medium 254 (Cascade Biologics (Oregon, USA)) with HMGS.
- HEM (1 ⁇ 10 5 ) was incubated for 24 hours in 6-cm dishes. Before exposure to 100 nM ⁇ -MSH (Sigma-Aldrich, St. Louis, MO, USA) for several days, 3,6-anhydro- L- galactose (L- at concentrations of 0, 25, 50, and 100 ⁇ g / mL was applied to the cells. AHG was treated for 1 hour.
- ⁇ -MSH Sigma-Aldrich, St. Louis, MO, USA
- Lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ⁇ -glycerophosphate, 1 mM Na 3 VO 4 , 1 g / mL Cells were lysed with leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet. Protein concentration was measured according to the manufacturer's instructions using a dye-bound protein assay kit (Bio-Rad Laboratories Inc. Hercules, CA, USA).
- TRP-1 expression was reduced in an L-AHG concentration dependent manner in HEMs (FIG. 10).
- L-AHG did not induce any significant reduction in tyrosinase activity of the mushrooms.
- Arbutin reduced tyrosinase activity by 40% at a concentration of 200 ⁇ M.
- L-AHG is a novel hypopigmentation agent that inhibits the expression of tyrosinase and TRP-1.
- Hyaluronan is a glycosaminoglycan composed of D-glucuronic acid and N-acetyl-D-glucosamine. Because of its ability to store large amounts of water, HA plays an important role in regulating water balance and osmotic pressure.
- AH is synthesized in the cell membrane by HAS 1, 2 and 3, in particular HAS2 is present in normal human tissues.
- HAS2 genetic deficiency of HAS2 causes prenatal lethality in mouse models and shows reduced HAS2 gene expression in the epidermis and dermis of the skin of adult humans. Thus, increasing HAS2 expression may be a good strategy for maintaining skin homeostasis.
- Western blot analysis was performed to determine the timing and concentration of L-AHG induction for HAS2 expression.
- the cells used are cultured at 37 °C under 5% CO 2 atmosphere using Dulbecco's modified Eagle's medium (DMEM , GIBCO ® Invitrogen, Auckland, NZ) of a 10% FBS and penicillin / streptomycin was added to HaCaT cells.
- DMEM Dulbecco's modified Eagle's medium
- Lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ⁇ -glycerophosphate, 1 mM Na 3 VO 4 , 1 g / mL Cells were lysed with leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail tablet. Protein concentration was measured according to the manufacturer's instructions using a dye-bound protein assay kit (Bio-Rad Laboratories Inc.).
- L-AHG increased HAS2 expression after 3 hours of treatment.
- L-AHG also increased HAS2 expression in a concentration dependent manner.
- HAS2 expression is regulated by various inflammatory signaling pathways such as MAPKs and AKT.
- various inflammatory signaling pathways such as MAPKs and AKT.
- the present invention may use 3,6-anhydro-L-galactose as a whitening or moisturizer, antioxidant, hypopigmentation agent, or anti-inflammatory agent.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (20)
- 제1항에 있어서, 3,6-안하이드로-L-갈락토오스는아가로오스와 0.5 내지 60%(w/v) 농도의 약산을 40 내지 150℃의 온도 범위에서 100 내지 200 rpm의 조건으로 30분 내지 6시간 동안 반응시켜 아가로올리고당을 제조하는 단계; 및상기 아가로올리고당과 아가로오스 분해효소 및 네오아가로바이오스 가수분해효소를 20 내지 40℃의 온도 범위에서 0 내지 200 rpm 조건으로 30분 내지 7일 동안 반응시키는 단계를 거쳐 제조되는 것인 피부 미백 또는 보습용 화장료 조성물.
- 제2항에 있어서,약산은 아세트산(Acetic acid), 포름산(Formic acid), 숙신산(Succinic acid), 시트르산(Citric acid), 말산(Malic acid), 말레산(Maleic acid) 및 옥살산(Oxalic acid)으로 이루어진 군으로부터 선택된 하나 이상인 피부 미백 또는 보습용 화장료 조성물.
- 제2항에 있어서,아가로오스 분해효소는 서열목록 서열번호 1에 기재된 아미노산 서열로 표시되는 피부 미백 또는 보습용 화장료 조성물.
- 제2항에 있어서,네오아가로바이오스 가수분해효소는 서열번호 3에 기재된 아미노산 서열로 표시되는 피부 미백 또는 보습용 화장료 조성물.
- 제6항에 있어서,피부 색소 침착 질환은 멜라닌 색소의 합성 증가로 피부에 국소적으로 발생하고, 기미, 주근깨, 흑색점, 모반, 약물에 의한 색소 침착, 염증 후 색소 침착, 또는 피부염에 발생하는 과색소 침착 중 어느 하나인 피부 색소 침착 질환의 예방 또는 치료용 약제학적 조성물.
- 제6항에 있어서, 3,6-안하이드로-L-갈락토오스는아가로오스와 0.5 내지 60%(w/v) 농도의 약산을 40 내지 150℃의 온도 범위에서 100 내지 200 rpm의 조건으로 30분 내지 6시간 동안 반응시켜 아가로올리고당을 제조하는 단계; 및상기 아가로올리고당과 아가로오스 분해효소 및 네오아가로바이오스 가수분해효소를 20 내지 40℃의 온도 범위에서 0 내지 200 rpm 조건으로 30분 내지 7일 동안 반응시키는 단계를 거쳐 제조되는 것인 피부 색소 침착 질환의 예방 또는 치료용 약제학적 조성물.
- 제8항에 있어서,약산은 아세트산(Acetic acid), 포름산(Formic acid), 숙신산(Succinic acid), 시트르산(Citric acid), 말산(Malic acid), 말레산(Maleic acid) 및 옥살산(Oxalic acid)으로 이루어진 군으로부터 선택된 하나 이상인 피부 색소 침착 질환의 예방 또는 치료용 약제학적 조성물.
- 제8항에 있어서,아가로오스 분해효소는 서열목록 서열번호 1에 기재된 아미노산 서열로 표시되는 피부 색소 침착 질환의 예방 또는 치료용 약제학적 조성물.
- 제8항에 있어서,네오아가로바이오스 가수분해효소는 서열번호 3에 기재된 아미노산 서열로 표시되는 피부 색소 침착 질환의 예방 또는 치료용 약제학적 조성물.
- 제12항에 있어서, 3,6-안하이드로-L-갈락토오스는아가로오스와 0.5 내지 60%(w/v) 농도의 약산을 40 내지 150℃의 온도 범위에서 100 내지 200 rpm의 조건으로 30분 내지 6시간 동안 반응시켜 아가로올리고당을 제조하는 단계; 및상기 아가로올리고당과 아가로오스 분해효소 및 네오아가로바이오스 가수분해효소를 20 내지 40℃의 온도 범위에서 0 내지 200 rpm 조건으로 30분 내지 7일 동안 반응시키는 단계를 거쳐 제조되는 것인 염증성 질환의 예방 또는 치료용 약제학적 조성물.
- 제13항에 있어서,약산은 아세트산(Acetic acid), 포름산(Formic acid), 숙신산(Succinic acid), 시트르산(Citric acid), 말산(Malic acid), 말레산(Maleic acid) 및 옥살산(Oxalic acid)으로 이루어진 군으로부터 선택된 하나 이상인 염증성 질환의 예방 또는 치료용 약제학적 조성물.
- 제13항에 있어서,아가로오스 분해효소는 서열목록 서열번호 1에 기재된 아미노산 서열로 표시되는 염증성 질환의 예방 또는 치료용 약제학적 조성물.
- 제13항에 있어서,네오아가로바이오스 가수분해효소는 서열번호 3에 기재된 아미노산 서열로 표시되는 염증성 질환의 예방 또는 치료용 약제학적 조성물.
- 아가로오스와 0.5 내지 60%(w/v) 농도의 약산을 40 내지 150℃의 온도 범위에서 100 내지 200 rpm의 조건으로 30분 내지 6시간 동안 반응시켜 아가로올리고당을 제조하는 단계; 및상기 아가로올리고당과 아가로오스 분해효소 및 네오아가로바이오스 가수분해효소를 20 내지 40℃의 온도 범위에서 0 내지 200 rpm 조건으로 30분 내지 7일 동안 반응시키는 단계를 포함하는 3,6-안하이드로-L-갈락토오스의 제조방법.
- 제17항에 있어서,약산은 아세트산(Acetic acid), 포름산(Formic acid), 숙신산(Succinic acid), 시트르산(Citric acid), 말산(Malic acid), 말레산(Maleic acid) 및 옥살산(Oxalic acid)으로 이루어진 군으로부터 선택된 하나 이상인 3,6-안하이드로-L-갈락토오스의 제조방법.
- 제17항에 있어서,아가로오스 분해효소는 서열목록 서열번호 1에 기재된 아미노산 서열로 표시되는 3,6-안하이드로-L-갈락토오스의 제조방법.
- 제17항에 있어서,네오아가로바이오스 가수분해효소는 서열번호 3에 기재된 아미노산 서열로 표시되는 3,6-안하이드로-L-갈락토오스의 제조방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380007372.0A CN105745329B (zh) | 2012-01-18 | 2013-01-18 | 3,6-脱水-l-半乳糖的制备方法及其用途 |
JP2014553259A JP6022603B2 (ja) | 2012-01-18 | 2013-01-18 | 皮膚美白用化粧料組成物、予防または治療用薬剤学的組成物、及び治療用薬剤学的組成物 |
US14/373,274 US20150216778A1 (en) | 2012-01-18 | 2013-01-18 | Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof |
US15/352,073 US20170071841A1 (en) | 2012-01-18 | 2016-11-15 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
US15/689,840 US10071041B2 (en) | 2012-01-18 | 2017-08-29 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
US16/100,337 US10639261B2 (en) | 2012-01-18 | 2018-08-10 | Method for preparing 3,6-anhydro-L-galactose, and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0005716 | 2012-01-18 | ||
KR20120005716 | 2012-01-18 | ||
KR10-2013-0005704 | 2013-01-18 | ||
KR1020130005704A KR101525298B1 (ko) | 2012-01-18 | 2013-01-18 | 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/373,274 A-371-Of-International US20150216778A1 (en) | 2012-01-18 | 2013-01-18 | Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof |
US15/352,073 Division US20170071841A1 (en) | 2012-01-18 | 2016-11-15 | Method for preparing 3,6-anhydro-l-galactose, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013109096A1 true WO2013109096A1 (ko) | 2013-07-25 |
Family
ID=48799463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/000423 WO2013109096A1 (ko) | 2012-01-18 | 2013-01-18 | 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013109096A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104498412A (zh) * | 2014-12-31 | 2015-04-08 | 南京农业大学 | 一种能降解琼脂的柯恩氏菌 |
CN107109447A (zh) * | 2014-10-01 | 2017-08-29 | 高丽大学校产学协力团 | 通过使用缓冲液预处理提高琼脂中单糖生产产率的方法 |
CN113881730A (zh) * | 2021-09-17 | 2022-01-04 | 华南师范大学 | L-半乳糖的合成方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6322814B1 (en) * | 1994-03-04 | 2001-11-27 | Ian James Miller | Manufacture of and uses for low molecular weight agars and agaroids |
EP1166786A1 (en) * | 1999-01-20 | 2002-01-02 | Takara Shuzo Co, Ltd. | Medicinal compositions |
EP1038879B1 (en) * | 1997-11-11 | 2009-04-01 | Takara Bio Inc. | Drugs, foods or drinks with the use of algae-derived physiologically active substances |
KR20100040438A (ko) * | 2008-10-10 | 2010-04-20 | 고려대학교 산학협력단 | 신규한 아가레이즈 및 이를 이용한 아가로스로부터 아가로올리고사카라이드의 효소적 생산방법 |
KR20100108241A (ko) * | 2009-03-27 | 2010-10-06 | 고려대학교 산학협력단 | 신규한 알파-네오 아가로바이오스 가수분해 효소 및 그를 이용한 단당류의 획득 방법 |
KR20110113287A (ko) * | 2010-04-09 | 2011-10-17 | 경희대학교 산학협력단 | 비단나무 추출물 발효액을 함유하는 미백 또는 주름개선용 조성물 |
KR101087265B1 (ko) * | 2009-12-23 | 2011-11-29 | 고려대학교 산학협력단 | 사카로파거스 데그러단스 2-40의 조효소를 이용한 3,6-안하이드로-l-갈락토오스와 갈락토오스 생산 및 3,6-안하이드로-l-갈락토오스 정량방법 |
-
2013
- 2013-01-18 WO PCT/KR2013/000423 patent/WO2013109096A1/ko active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6322814B1 (en) * | 1994-03-04 | 2001-11-27 | Ian James Miller | Manufacture of and uses for low molecular weight agars and agaroids |
EP1038879B1 (en) * | 1997-11-11 | 2009-04-01 | Takara Bio Inc. | Drugs, foods or drinks with the use of algae-derived physiologically active substances |
EP1166786A1 (en) * | 1999-01-20 | 2002-01-02 | Takara Shuzo Co, Ltd. | Medicinal compositions |
KR20100040438A (ko) * | 2008-10-10 | 2010-04-20 | 고려대학교 산학협력단 | 신규한 아가레이즈 및 이를 이용한 아가로스로부터 아가로올리고사카라이드의 효소적 생산방법 |
KR20100108241A (ko) * | 2009-03-27 | 2010-10-06 | 고려대학교 산학협력단 | 신규한 알파-네오 아가로바이오스 가수분해 효소 및 그를 이용한 단당류의 획득 방법 |
KR101087265B1 (ko) * | 2009-12-23 | 2011-11-29 | 고려대학교 산학협력단 | 사카로파거스 데그러단스 2-40의 조효소를 이용한 3,6-안하이드로-l-갈락토오스와 갈락토오스 생산 및 3,6-안하이드로-l-갈락토오스 정량방법 |
KR20110113287A (ko) * | 2010-04-09 | 2011-10-17 | 경희대학교 산학협력단 | 비단나무 추출물 발효액을 함유하는 미백 또는 주름개선용 조성물 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107109447A (zh) * | 2014-10-01 | 2017-08-29 | 高丽大学校产学协力团 | 通过使用缓冲液预处理提高琼脂中单糖生产产率的方法 |
CN104498412A (zh) * | 2014-12-31 | 2015-04-08 | 南京农业大学 | 一种能降解琼脂的柯恩氏菌 |
CN113881730A (zh) * | 2021-09-17 | 2022-01-04 | 华南师范大学 | L-半乳糖的合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101573651B1 (ko) | 3,6―안하이드로―l―갈락토오스의 제조방법 및 이의 용도 | |
WO2017026855A1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 피부상태 개선용 조성물 | |
WO2013058594A2 (ko) | 항염 활성을 갖는 발효녹용 추출물의 제조 방법, 이로부터 얻어진 추출물 및 이러한 추출물의 용도 | |
WO2017135556A1 (ko) | Gdf11을 포함하는 조성물 및 그의 용도 | |
WO2021049852A1 (ko) | 피부 주름 개선능을 갖는 고기능성 천연 대사산물을 생산하는 락토바실러스 파라카세이 아종 톨러란스 sw1 균주 및 이의 용도 | |
WO2020171285A1 (ko) | 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 | |
WO2020218781A1 (ko) | 불멸화 줄기세포 유래 엑소좀 풍부 배양액 및 장미꽃봉오리 추출물을 유효성분으로 포함하는 기능성 조성물 | |
WO2018164369A1 (ko) | 효소 처리된 무궁화 추출물을 유효성분으로 함유하는 피부 주름 개선용 조성물 | |
WO2022050559A1 (ko) | 데이노잔틴 발효추출물의 제조방법 및 데이노잔틴 발효추출물을 포함하는 화장료 조성물 | |
WO2013109096A1 (ko) | 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도 | |
WO2015041498A1 (ko) | 네오아가로올리고당을 포함하는 면역 증강용 또는 항암용 조성물 | |
WO2016159580A1 (ko) | 티아사포제놀 유도체를 유효성분으로 포함하는 조성물 | |
WO2018111042A2 (ko) | 한약재 추출물을 유효성분으로 포함하는 화장료 조성물 | |
WO2017065546A1 (ko) | 3,6-안하이드로-l-갈락토오스의 항충치 용도 | |
WO2014157910A1 (ko) | 효소처리 타나까 추출물을 함유하는 조성물 | |
WO2021075929A1 (ko) | 애엽 추출물을 포함하는 피부 손상 개선용 조성물 | |
WO2017074163A1 (ko) | 초저분자 케라틴 펩타이드의 제조 방법 및 그의 이용 | |
WO2018194261A1 (ko) | 4'-o-메틸알피눔 이소플라본의 치료적 용도 | |
WO2018155933A1 (ko) | 아쿠아포린-3의 발현을 증가시키는 6,7-디메톡시-2,2-디메틸-2h-크로멘 및 이의 용도 | |
WO2022124871A1 (ko) | 락토바실러스 속 균주, 유박테리움 속 균주 또는 코프로코커스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 | |
WO2022039572A1 (ko) | 포로스테레움속 신균주 Porostereum sp.(KCTC18837P) 균사체 배양물 및 이를 포함하는 피부상태 개선용 화장료 조성물 | |
WO2023055051A1 (ko) | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 | |
WO2023219265A1 (ko) | 플라즈마 처리된 에르고스테롤 반응물의 제조방법, 상기 제조방법으로 제조된 반응물, 이로부터 분리된 화합물 및 이의 용도 | |
WO2023055055A1 (ko) | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 | |
WO2023055054A1 (ko) | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13738901 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014553259 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14373274 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13738901 Country of ref document: EP Kind code of ref document: A1 |